The manufacturing records for the onxmc-23 sn (b)(4) were reviewed and it was confirmed that all records were controlled, available for review, and met all specifications per the device master record.All lots passed functional testing and met release specifications.During the investigation no non-conformances or deviations were noted.A review was performed of the available information.The onxm-23 sn (b)(4) implanted (b)(6) 2016 in the mitral position as part of a double valve replacement (dvr) procedure in which a st.Jude valve was implanted in the aortic position.The patient died the next day of unknown cause following two arrest episodes.Per the guidelines for reporting morbidity and mortality in cardiac valve interventions, this would be classified as an early sudden, unexplained death; a valve-related mortality [akins 2008].Although relatively rare, death is a recognized potential adverse event associated with heart valve replacement [instructions for use].For example, chambers, et al., reporting on a 12-year follow-up study of on-x patients, showed no early sudden deaths, but did have 3 out of 70 double valve recipients with cardiac related early deaths.As the cause is classified as an early sudden, unexplained death, we cannot, by definition, speculate on the cause of death.There is too little information to establish what, if any, relationship the on-x valve has to the event.No further action is warranted.This event does not identify additional hazards or modify the probability and severity of existing hazards.
|